Page 14 - Read Online

Page 8 of 10 Wang et al. Hepatoma Res 2018;4:14 I http://dx.doi.org/10.20517/2394-5079.2018.16

carcinoma patients after second hepatectomy. J Surg Res 2016;200:82-90.
11. Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z. Transarterial chemoembolization versus radiofrequency ablation
for recurrent hepatocellular carcinoma after resection within Barcelona clinic liver cancer stage 0/A: a retrospective comparative study.
J Vasc Interv Radiol 2016;27:1829-36.
12. Sun WC, Chen IS, Liang HL, Tsai CC, Chen YC, Wang BW, Lin HS, Chan HH, Hsu PI, Tsai WL, Cheng JS. Comparison of repeated
surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection. Oncotarget
2017;8:104571-81.
13. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
14. Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J. Practice guidelines for the pathological diagnosis of primary liver cancer:
2015 update. World J Gastroenterol 2016;22:9279-87.
15. Cong WM, Wu MC. New insights into molecular diagnostic pathology of primary liver cancer: advances and challenges. Cancer letters
2015;368:14-9.
16. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci 1967;58:1468-71.
17. Fialkow PJ, Klein G, Gartler SM, Clifford P. Clonal origin for individual Burkitt tumours. Lancet 1970;1:384-6.
18. Van Etten JL, Dehm SM. Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer 2016;23:R207-17.
19. Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, Schizas M, De Brot M, Andrade VP, Mauguen A, Seshan VE, King
TA. Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Res 2016;18:66.
20. Baker AM, Graham TA, Wright NA. Pre-tumour clones, periodic selection and clonal interference in the origin and progression of
gastrointestinal cancer: potential for biomarker development. J Pathol 2013;229:502-14.
21. Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH, Holt RA. Clonal evolution of high-grade
serous ovarian carcinoma from primary to recurrent disease. J Pathol 2013;229:515-24.
22. Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, Beachy PA. Cellular origin of bladder neoplasia and tissue dynamics
of its progression to invasive carcinoma. Nature Cell Biol 2014;16:469-78.
23. Fialkow PJ. Clonal origin of human tumors. Rev Cancer 1976;458:283-321.
24. Nomoto S, Hishida M, Inokawa Y, Sugimoto H, Kodera Y. Management of hepatocellular carcinoma should consider both tumor factors
and background liver factors. Hepatobil Surg Nutr 2014;3:82-5.
25. Feng LH, Dong H, Lau WY, Yu H, Zhu YY, Zhao Y, Lin YX, Chen J, Wu MC, Cong WM. Novel microvascular invasion-based
prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin
Oncol 2017;143:293-303.
26. Cong WM, Dong H, Zhu YY, Zhu Z. Malignant tumors of the liver and intrahepatic bile ducts. In: Cong WM, editor. Surgical pathology
of hepatobiliary tumors. Singapore: Springer Nature Singapore; 2017. p. 145-8.
27. Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature 2016;529:298-306.
28. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017;168:613-28.
29. Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nature Rev
Cancer 2014;14:77-91.
30. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva
A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct
molecular entity. J Hepatol 2017;66:952-61.
31. Xue R, Li R, Guo H, Guo L, Su Z, Ni X, Qi L, Zhang T, Li Q, Zhang Z, Xie XS, Bai F, Zhang N. Variable intra-tumor genomic
heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology 2016;150:998-1008.
32. Duan M, Hao J, Cui S, Worthley DL, Zhang S, Wang Z, Shi J, Liu L, Wang X, Ke A, Cao Y, Xi R, Zhang X, Zhou J, Fan J, Li C, Gao
Q. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res
2018;28:359-73.
33. Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, Jin GZ, Cong WM, Wu MC. Determination of clonal origin of recurrent
hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg
2013;217:1054-62.
34. Wang Z, Gong W, Shou D, Zhang L, Gu X, Wang Y, Teng D, Zheng H. Clonal origin of hepatocellular carcinoma and recurrence after
liver transplantation. Ann Transplant 2016;21:484-90.
35. de’Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a
systematic review. World J Gastroenterol 2015;21:11185-98.
36. Choi SI, Yu A, Kim BH, Ko EJ, Park SS, Nam BH, Park JW. A model predicting survival of patients with recurrent or progressive
hepatocellular carcinoma: the MORE score. J Gastroenterology Hepatol 2017;32:651-8.
37. Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing
recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg
2017;266:118-25.
38. Nagai S, Mangus RS, Kubal CA, Ekser B, Fridell JA, Klingler KR, Maluccio MA, Tector AJ. Prognosis after recurrence of
hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival. Clin Transplant 2015;29:1156-63.
39. Na GH, Hong TH, You YK, Kim DG. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver
transplantation. World J Gastroenterol 2016;22:5790-9.
40. Muaddi H, Al-Adra DP, Beecroft R, Ghanekar A, Moulton CA, Doyle A, Selzner M, Wei A, McGilvray ID, Gallinger S, Grant DR,